These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2664894)

  • 1. Functional interactions of 2-phenylethylamine and of tryptamine with brain catecholamines: implications for psychotherapeutic drug action.
    Greenshaw AJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(3-4):431-43. PubMed ID: 2664894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Phenylethylamine-induced changes in catecholamine receptor density: implications for antidepressant drug action.
    Paetsch PR; Greenshaw AJ
    Neurochem Res; 1993 Sep; 18(9):1015-22. PubMed ID: 7901780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and neurochemical studies on N-propargyl-2-phenylethylamine, a prodrug of 2-phenylethylamine.
    Rao TS; Baker GB; Coutts RT
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Jul; 336(1):25-32. PubMed ID: 3627289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenylethylamine modulation of affect: therapeutic and diagnostic implications.
    Sabelli HC; Javaid JI
    J Neuropsychiatry Clin Neurosci; 1995; 7(1):6-14. PubMed ID: 7711493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine.
    Baker GB; Coutts RT; Rao TS
    Br J Pharmacol; 1987 Oct; 92(2):243-55. PubMed ID: 2890391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors.
    Bergman J; Yasar S; Winger G
    Psychopharmacology (Berl); 2001 Dec; 159(1):21-30. PubMed ID: 11797065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N,N-dipropargyl-2-phenylethylamine, a potential prodrug of 2-phenylethylamine: neurochemical and neuropharmacological studies in rat.
    Rao TS; Baker GB; Coutts RT
    Brain Res Bull; 1987 Jul; 19(1):47-55. PubMed ID: 3651840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of monofluoromethyldopa (MFMD) on trace amine levels.
    Dyck LE
    Life Sci; 1987 Feb; 40(6):571-5. PubMed ID: 3807650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation.
    Braestrup C; Andersen H; Randrup A
    Eur J Pharmacol; 1975 Nov; 34(1):181-7. PubMed ID: 1241962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent studies on the MAO inhibitor phenelzine and its possible metabolites.
    McKenna KF; Baker GB; Coutts RT; Rauw G; Mozayani A; Danielson TJ
    J Neural Transm Suppl; 1990; 32():113-8. PubMed ID: 1982447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenylethylamine in the CNS: effects of monoamine oxidase inhibiting drugs, deuterium substitution and lesions and its role in the neuromodulation of catecholaminergic neurotransmission.
    Boulton AA; Juorio AV; Paterson IA
    J Neural Transm Suppl; 1990; 29():119-29. PubMed ID: 2193105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors.
    Ortmann R; Schaub M; Felner A; Lauber J; Christen P; Waldmeier PC
    Psychopharmacology (Berl); 1984; 84(1):22-7. PubMed ID: 6436886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
    Miklya I
    Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
    Yoneda F; Moto T; Sakae M; Ohde H; Knoll B; Miklya I; Knoll J
    Bioorg Med Chem; 2001 May; 9(5):1197-212. PubMed ID: 11377178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain levels of 5-hydroxytryptamine, tryptamine and 2-phenylethylamine in the rat after administration of N-cyanoethyltranylcypromine.
    Baker GB; Nazarali AJ; Coutts RT; Micetich RG; Hall TW
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(4-6):657-60. PubMed ID: 6531437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminative stimulus properties of beta-phenylethylamine, deuterated beta-phenylethylamine, phenylethanolamine and some metabolites of phenylethylamine in rodents.
    Reid D; Goudie AJ
    Pharmacol Biochem Behav; 1986 Jun; 24(6):1547-53. PubMed ID: 3737623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical plasticity of synaptic transmission: a critical review of Dale's Principle.
    Sabelli HC; Mosnaim AD; Vazquez AJ; Giardina WJ; Borison RL; Pedemonte WA
    Biol Psychiatry; 1976 Aug; 11(4):481-524. PubMed ID: 9160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic measurements of the turnover rates of phenylethylamine and tryptamine in vivo in the rat brain.
    Durden DA; Philips SR
    J Neurochem; 1980 Jun; 34(6):1725-32. PubMed ID: 7381498
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat.
    Dyck LE; Boulton AA
    Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.